MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Evotec AG

Fechado

SetorFinanças

7.33 0.27

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.12

Máximo

7.42

Indicadores-chave

By Trading Economics

Rendimento

-1.2M

-41M

Vendas

36M

221M

Margem de lucro

-18.46

Funcionários

4,740

EBITDA

58M

-45M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+39.37% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.1B

Abertura anterior

7.06

Fecho anterior

7.33

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Evotec AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de jun. de 2024, 13:17 UTC

Conversa de Mercado

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Comparação entre Pares

Variação de preço

Evotec AG Previsão

Preço-alvo

By TipRanks

39.37% parte superior

Previsão para 12 meses

Média 10.23 EUR  39.37%

Máximo 12.1 EUR

Mínimo 7 EUR

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Evotec AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.818 / 7.348Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.